Table 3.

Comparison of cumulative incidences and risks of long-term sequelae between SNJ cases of varying severity and the reference cohort.

Different categories	Reference neonates (n = 12,579)		SNJ (level of severity)
			Phototherapy (n = 48,124)				Intensive phototherapy (n = 10,171)				ET (n = 256)
	n	%	n	%	OR	aORa	n	%	OR	aORa	n	%	OR	aORa
Developmental delay	614	4.88	4,669	9.70	1.78***	1.59***	1,058	10.40	1.94***	1.72***	53	20.70	3.37***	3.17***
Infantile cerebral palsy	63	0.50	664	1.38	1.68**	1.25	173	1.70	1.67*	1.4*	19	7.42	7.99**	5.08***
Lack of expected normal physiological development in childhood	218	1.73	1,524	3.17	1.55***	1.42***	359	3.53	1.55***	1.55***	18	7.03	3.03*	2.94***
Hearing loss	169	1.34	1,427	2.97	1.75***	1.62***	327	3.22	2.19***	1.73***	37	14.45	10.01***	5.71***
Developmental speech disorder	250	1.99	1,806	3.75	1.69***	1.51***	411	4.04	1.78***	1.63***	29	11.33	4.50***	4.5***
Dysarthria	178	1.42	1,084	2.25	1.58***	1.39***	258	2.54	1.77***	1.45***	12	4.69	3.60**	2.39*
Mental retardation	118	0.94	798	1.66	1.35**	1.2	172	1.69	1.39*	1.23	14	5.47	3.46*	2.16*
ADHD	324	2.58	1,792	3.72	1.46***	1.24***	396	3.89	1.49***	1.26**	10	3.91	2.26	1.04
Autism	61	0.48	416	0.86	1.82***	1.5**	98	0.96	2.14***	1.59**	2	0.78	1.75	0.83

SNJ significant neonatal jaundice, ET exchange transfusion, ADHD attention deficit hyperactivity disorder.

*P 0.05; **P 0.01; ***P 0.001.

^aAdjusted for gender, urbanization levels, and comorbid perinatal conditions (prematurity, hemolytic disease of newborn, and congenital or chromosome anomalies).